pubs.acs.org/joc
aldehydes4 and imines,5 oxidations of thioethers,6 trime-
Improved Synthesis of Enantiopure
4-Hydroxy[2.2]paracyclophane
thylsilylcyanation,7 and allylboration.8
Most of such ligands can be described as derivatives of
4-hydroxy[2.2]paracyclophane (3) and are obtainable from
this compound.
€
Christian J. Friedmann, Sefer Ay, and Stefan Brase*
Since its first synthesis by Cram in 1955,9 much effort has
been made to develop more efficient synthesis protocols to
this compound.10,11 Today, 3 is usually prepared on a large
scale by a method developed by Krohn and Hopf (Scheme 1).12
Institute of Organic Chemistry, Karlsruhe
Institute of Technology, Fritz-Haber-Weg 6,
D-76131 Karlsruhe, Germany
SCHEME 1. Conventional Synthesis of 312
Received March 20, 2010
Starting from unsubstituted [2.2]paracyclophane (1), an aro-
matic substitution with bromine under iron catalysis is carried
out. The obtained 4-bromo[2.2]paracyclophane (2) is then
converted into the desired product by a one-pot proce-
dure consisting of a Br-Li exchange, transmetalation onto
boron, and an oxidative workup with a mixture of potassium
hydroxide and hydrogen peroxide. Although this procedure is
accomplishable, the second step is usually critical, and the yield
ranges from 6513 to 82%.14
In order to obtain enantiopure material, the subsequent
resolution requires two additional steps. Auxiliaries known
in the literature15 for this purpose are acid chlorides, derived
from camphanic acid (4)16 and naproxene (5, Figure 1),17
which convert 3 into the corresponding diastereomeric
4-Hydroxy[2.2]paracyclophane is readily prepared via an
improved synthetic protocol from unsubstituted [2.2]para-
cyclophane. The key step is a Dakin oxidation of 4-formyl-
[2.2]paracyclophane. This allows a rapid access to large
quantities of the product and an easy synthesis of the
enantiopure form.
The synthesis of enantiopure ligands has attained consid-
erable attention due to their pivotal role in asymmetric
synthesis, and consequently, the need for efficient routes to
such compounds is of increasing interest. In the field of
asymmetric catalysis, mono- and bidentate ligands based on
a [2.2]paracyclophane scaffold1 (1) have been successfully
employed as potent catalysts2 in different kinds of reactions,
like asymmetric hydrogenations,3 addition reactions to
(9) In his pioneering work on paracyclophane chemistry, Cram identified
3 as a byproduct in his attempts to reduce the corresponding diazonium salt
with hypophosphoric acid: Cram, D. J.; Allinger, N. L. J. Am. Chem. Soc.
1955, 77, 6289–6294.
(10) (a) Cram, D. J.; Day, A. C. J. Org. Chem. 1966, 31, 1227–1232.
(b) Norcross, B. E.; Becker, D; Cukier, R. I.; Schultz, R. M. J. Org. Chem.
1967, 32, 220–222.
(11) Other examples, apart from methods described elsewhere: (a)
Zhuravsky, R.; Starikova, Z.; Vorontsov, E.; Rozenberg, V. Tetrahedron:
Asymmetry 2008, 19, 216–222. (b) Rozenberg, V.; Zhuravsky, R.; Sergeeva,
E. Chirality 2006, 18, 95–102. (c) Hitchcock, P. B.; Rowlands, G. J.; Parmar,
R. Chem. Commun. 2005, 4219–4221. (d) Vorontsova, N.; Rozenberg, V.;
Vorontsov, E.; Antonov, D.; Starikova, Z. Eur. J. Org. Chem. 2003, 761–770.
(e) Braddock, D. C.; MacGilp, I. D.; Perry, B. G. J. Org. Chem. 2002, 67,
8679–8681. (f) Rozenberg, V.; Danilova, T.; Sergeeva, E.; Vorontsov, E.;
Starikova, Z.; Korlyukov, A.; Hopf, H. Eur. J. Org. Chem. 2002, 468–477. (g)
Cipiciani, A.; Fringuelli, F.; Mancini, V.; Piermatti, O.; Scappini, A. M.;
Ruzziconi, R. Tetrahedron 1997, 53, 11853–11858.
(1) Modern Cyclophane Chemistry; Gleiter, R., Hopf, H., Eds.; Wiley-
VCH: Weinheim, 2004.
(2) For a general review, see: Gibson, S. E.; Knight, J. D Org. Biomol.
Chem. 2003, 1, 1256–1269.
(3) With phosphorous-based ligands: (a) Zanotti-Gerosa, A.; Malan, C.;
Herzberg, D. Org. Lett. 2001, 3, 3687–3690. (b) Pye, P. J.; Rossen, K.;
Reamer, R. A.; Tsou, N. N.; Volante, R. P.; Reider, P. J. J. Am. Chem. Soc.
1997, 119, 6207–6208.
€
(4) 1,4-Additions: Ay, S.; Nieger, M.; Brase, S. Chem.;Eur. J. 2008, 14,
11539–11556. 1,2-Additions: (a) Bolm, C.; Whelligan, D. K. Adv. Synth.
(12) Krohn, K.; Rieger, H.; Hopf, H.; Barrett, P. G. Chem. Ber. 1990, 123,
1729–1732.
(13) Results from our laboratories.
(14) Kane, V. V.; Gerdes, A.; Grahn, W.; Ernst, L.; Dix, I.; Jones, P. G.;
Hopf, H. Tetrahedron Lett. 2001, 42, 373–376.
€
Catal. 2006, 348, 2093–2100. (b) Lauterwasser, F.; Gall, J.; Hofener, S.;
Brase, S. Adv. Synth. Catal. 2006, 348, 2068–2074. (c) Lauterwasser, F.;
€
€
Nieger, M.; Mansikkamaki, H.; Nattinen, K.; Brase, S. Chem.;Eur. J. 2005,
€
€
11, 4509–4525.
(5) (a) Hermanns, N.; Dahmen, S.; Bolm, C.; Brase, S. Angew. Chem., Int.
(15) Only indirect resolution methods using enzymes are known. In all
cases, 4-acetoxy[2.2]paracyclophane is used as a substrate hydrolyzed via
kinetic resolution to enantioenriched 3: (a) Pamperin, D.; Schulz, C.; Hopf,
H.; Syldatk, C.; Pietzsch, M. Eur. J. Org. Chem. 1998, 1441–1445. (b)
Pamperin, D.; Ohse, B.; Hopf, H.; Pietzsch, M. J. Mol. Catal. B: Enzym.
1998, 317–319. (c) Cipiciani, A.; Fringuelli, F.; Mancini, V.; Piermatti, O.;
Scappini, A. M.; Ruzziconi, R. Tetrahedron 1997, 53, 11853–11858.
(16) Rozenberg, V.; Danilova, T.; Sergeeva, E.; Vorontsov, E.; Starikova,
Z.; Korlyukov, A.; Hopf, H. Eur. J. Org. Chem. 2002, 3, 468–477.
(17) Zhang, T.-Z.; Dai, L.-X.; Hou, X.-L. Tetrahedron: Asymmetry 2007,
18, 251–259.
€
Ed. 2002, 41, 3692–3694. (b) Dahmen, S.; Brase, S. J. Am. Chem. Soc. 2002,
124, 5940–5941.
€
(6) Vetter, A. H.; Berkessel, A. Tetrahedron Lett. 1998, 39, 1741–1744.
(7) Belokon, Y.; Moscalenko, M.; Ikonnikov, N.; Yashkina, L.;
Antonov, D.; Vorontsov, E; Rozenberg, V. Tetrahedron: Asymmetry 1997,
8, 3245–3250.
(8) Vorontsova, N. V.; Zhuravsky, R. P.; Sergeeva, E. V.; Vorontsov,
E. V.; Starikova, Z. A.; Rozenberg, V. I. Russ. Chem. Bull. 2007, 546, 2225–
2231.
4612 J. Org. Chem. 2010, 75, 4612–4614
Published on Web 06/04/2010
DOI: 10.1021/jo100468s
r
2010 American Chemical Society